- argenx SE at Barclays Global Healthcare Conference TranscriptMar 12, 2024
- Q4 2023 argenx SE Earnings Call TranscriptFeb 29, 2024€345 (-8.44%)Earnings
- argenx SE at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus TranscriptDec 20, 2023
- argenx SE Investor Call TranscriptNov 28, 2023
- Q3 2023 argenx SE Earnings Call TranscriptOct 31, 2023Earnings
- argenx SE at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- argenx SE at Citi BioPharma Conference TranscriptSep 06, 2023
- Q2 2023 argenx SE Earnings Call TranscriptJul 27, 2023€469 (-1.43%)Earnings
- argenx SE To Discuss the Adhere Results TranscriptJul 17, 2023
- argenx SE To Discuss Drug Administration Approval of VYVGART TranscriptJun 21, 2023
- argenx SE at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 argenx SE Earnings Call TranscriptMay 04, 2023€355 (-0.03%)Earnings
- argenx SE at TD Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 argenx SE Earnings Call TranscriptMar 02, 2023€336.9 (-2.57%)Earnings
- argenx SE Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:00 AM TranscriptJan 09, 2023
- argenx SE at Piper Sandler Healthcare Conference TranscriptNov 30, 2022
- argenx SE at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 29, 2022
- Q3 2022 argenx SE Earnings Call TranscriptOct 27, 2022€379 (-1.99%)Earnings
- Q2 2022 argenx SE Earnings Call TranscriptJul 28, 2022€381 (+5.19%)Earnings
- argenx SE at Goldman Sachs Global Healthcare Conference TranscriptJun 15, 2022
- argenx SE at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Q1 2022 argenx SE Earnings Call TranscriptMay 05, 2022€287 (+2.94%)Earnings
- argenx SE Topline Phase 3 Data From ADAPT-SC Study Call TranscriptMar 22, 2022
- argenx SE at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Q4 2021 argenx SE Earnings Call TranscriptMar 03, 2022€254.6 (-3.19%)Earnings
- argenx SE at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- argenx SE To Discuss FDA Approval Call TranscriptDec 17, 2021
- Q3 2021 argenx SE Earnings Call TranscriptOct 28, 2021€238 (-1.45%)Earnings
- argenx SE at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 argenx SE Earnings Call TranscriptJul 29, 2021€252 (+0.80%)Earnings
- argenx SE virtual R&D Day Call TranscriptJul 20, 2021
- argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 08, 2021
- Q1 2021 argenx SE Earnings Call TranscriptMay 14, 2021€219.5 (+1.25%)Earnings
- argenx SE Presents At Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Full Year 2020 argenx SE Earnings Call TranscriptMar 04, 2021€252.8 (-6.30%)Earnings
- argenx SE - Special Call TranscriptFeb 01, 2021
- argenx SE at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- argenx SE at Stifel Virtual Healthcare Conference TranscriptNov 17, 2020
- Q3 2020 argenx SE Earnings Call TranscriptOct 22, 2020€217 (-1.00%)Earnings
- argenx SE at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- argenx SE at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Half Year 2020 argenx SE Earnings Call TranscriptJul 30, 2020€211 (-3.12%)Earnings
- argenx SE at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- argenx SE Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis - Call TranscriptMay 26, 2020
- Q1 2020 argenx SE Earnings and Business Update Call TranscriptMay 14, 2020
- argenx SE at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 12, 2020
- Q4 2019 argenx SE Earnings Call TranscriptFeb 27, 2020€135 (-1.39%)Earnings
- argenx SE at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- argenx SE at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 argenx SE Earnings Call TranscriptAug 01, 2019€128.1 (+0.63%)Earnings
- argenx SE - Special Call TranscriptMay 22, 2019
- Q4 2018 argenx SE Earnings Call TranscriptFeb 28, 2019€114.6 (+0.70%)Earnings
argenx SE at Goldman Sachs Global Healthcare Conference Transcript
Okay. Ladies and gentlemen, welcome to our next session where I'm very pleased to be joined by the team from argenx. I'm [Nick Hallett], I work in the European biopharma team in London. I'm joined today by Keith Woods, Chief Operating Officer; and Beth DelGiacco, the VP of IR. So first of all, welcome to both. It's great to have you here.
Thank you for having us. Pleasure to be here.
Questions & Answers
Perhaps, Keith, if we could start, if you could just sort of give a high-level overview of where argenx stands today, where your therapeutic area of focus is?
Sure. So as you know, at argenx, we were born out of engineering antibodies for other companies. Our ambition has expanded into clinical development, and we've kept some of those discoveries in-house first and foremost, is efgartigimod, VYVGART. We now have commercially launched VYVGART in the U.S. and Japan. So we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)